Dyadic International, Inc., a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, has completed the expansion of its research laboratory in The Netherlands.
The inauguration will be held on March 6, 2014 where customers, suppliers, partners and investors will be invited to tour the facility in Wageningen.
Dyadic’s chief operating officer, Danai Brooks, stated, “Commercial interest in Dyadic’s C1 expression technology has increased with new end markets, such as biopharmaceuticals, and new customers, such as BASF. By investing in our R&D capabilities, we are able to expand our new product development pipeline, take on additional projects with our strategic partners, and invest in strengthening the technology platform. We are extremely excited about several new projects commencing in 2014 and we expect to provide additional details about these projects in the coming weeks.”
Floor space at Dyadic Netherlands has significantly increased, allowing for the installation of a wide range of state-of-the-art research equipment including a new fermentation lab. In addition, the expansion will facilitate the housing of new scientists who were recently hired for the new C1-technology projects.
Dyadic increased its scientific staff by 40 per cent in 2013 and plans to continue hiring molecular biologists, enzymologists and fermentation specialists through 2014.
Wim van der Wilden, general manager of Dyadic Netherlands, added, “The expansion was necessary to meet the projected needs of the market. In the past year we have seen a growing interest for our C1 system with commercial and academic parties. Having these state-of-the-art facilities, in combination with a larger scientific staff, will allow us to take on additional projects while broadening our services to the market. This expansion strengthens the position of Dyadic Netherlands as a preferred partner for companies throughout the biotechnology industry who want to leverage Dyadic’s C1 technology, or who do not have the requisite in-house research skills.”